XML 44 R23.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Acquisition-Related Amortization and Remeasurement | 12 Months Ended
--- | ---
Dec. 31, 2021
Acquisition Related Amortization And Remeasurement [Abstract] |
Acquisition-Related Amortization and Remeasurement |
17. | Acquisition-related amortization and remeasurement
Acquisition-related amortization and remeasurement consists of (i) amortization related to intangible assets acquired through business combinations or asset acquisitions, (ii) the remeasurement of any related contingent consideration arrangement, (iii) recognized costs associated with acquired in-process research and development (“IPR&D”) assets, which are recognized immediately upon acquisition, and (iv) impairments of goodwill related to previously recognized business combinations. Components of acquisition-related amortization and remeasurement for the years ended December 31, 2021, 2020, and 2019, respectively, are as follows:
|  | Year Ended December 31, |
(U.S. Dollars, in thousands) |  | 2021 |  |  | 2020 |  |  | 2019 |
Changes in fair value of contingent consideration |  | $ | (3,575 | ) |  | $ | (7,300 | ) |  | $ | 29,140 |
Amortization of acquired intangibles |  |  | 7,907 |  |  |  | 6,801 |  |  |  | 5,072 |
Acquired IPR&D |  |  | 1,500 |  |  |  | — |  |  |  | — |
Impairment of Global Orthopedics goodwill |  |  | 11,756 |  |  |  | — |  |  |  | — |
Total |  | $ | 17,588 |  |  | $ | (499 | ) |  | $ | 34,212 |
Related Party Asset Acquisition On February 2, 2021, the Company entered into a technology assignment and royalty agreement with a medical device technology company partially owned and controlled by the wife of President and Chief Executive Officer, Jon Serbousek, whereby the Company acquired the intellectual property rights to certain assets for consideration of up to $10.0 million. Consideration was comprised of $1.0 million due at signing, which was recognized immediately as acquired IPR&D expense within acquisition-related amortization and remeasurement, and $9.0 million in contingent consideration. The contingent consideration is dependent upon multiple milestones, such as receipt of 510(k) clearance and the attainment of certain net sales targets. The Company accounted for this transaction as an asset acquisition. As the transaction is classified as an asset acquisition, the value of the consideration associated with the contingent milestones will be recognized at the time that applicable contingencies are resolved and consideration is paid or becomes payable. In addition, the Company is obligated to pay a royalty of 2% to 4% on net sales, commencing upon commercialization of the assets. The transaction was approved by the Company’s Audit and Finance Committee, with the Audit and Finance Committee directly supervising the negotiations of the transaction. Mr. Serbousek was excluded from such discussions and did not participate in the negotiation or evaluation of the transaction. Mr. Serbousek also continues to be excluded from the oversight of the Company’s development and commercialization activities in relation to the acquired technology and all other matters relating to the relationship between the Company and the counterparty IGEA S.p.A Asset Acquisition On April 7, 2021, the Company entered into an Exclusive License and Distribution Agreement (the “License Agreement”) with IGEA S.p.A (“IGEA”), an Italian manufacturer and distributor of bone and cartilage stimulation systems. As consideration for the License Agreement, the Company agreed to pay up to $4.0 million, with certain payments contingent upon reaching an FDA milestone. Of this amount, $0.5 million was paid in 2021, which was recognized as acquired IPR&D costs within acquisition-related amortization and remeasurement. The License Agreement also includes certain minimum purchase requirements.

X
- Definition Acquisition-related amortization and remeasurement. + References No definition available. + Details
Name: | ofix_AcquisitionRelatedAmortizationAndRemeasurementAbstract
Namespace Prefix: | ofix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Acquisition-related amortization and remeasurement disclosure. + References No definition available. + Details
Name: | ofix_AcquisitionRelatedAmortizationAndRemeasurementDisclosureTextBlock
Namespace Prefix: | ofix_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration